Don B Sanders1, George M Solomon2, Valeria V Beckett3, Natalie E West4, Cori L Daines5, Sonya L Heltshe6, Donald R VanDevanter7, Jonathan E Spahr8, Ronald L Gibson9, Jerry A Nick10, Bruce C Marshall11, Patrick A Flume12, Christopher H Goss13. 1. Department of Pediatrics, University of Wisconsin-Madison, Madison, WI, USA. Electronic address: dbsand@iu.edu. 2. Department of Medicine, Gregory Fleming James Cystic Fibrosis Center, University of Alabama at Birmingham, Birmingham, AL, USA. 3. Cystic Fibrosis Foundation Therapeutics Development Network Coordinating Center, Seattle Children's Research Institute, Seattle, WA, USA. 4. Department of Medicine, Johns Hopkins University, Baltimore, MD, USA. 5. Department of Pediatrics, University of Arizona, Tucson, AZ, USA. 6. Cystic Fibrosis Foundation Therapeutics Development Network Coordinating Center, Seattle Children's Research Institute, Seattle, WA, USA; Department of Pediatrics, University of Washington School of Medicine, Seattle, WA, USA. 7. Department of Pediatrics, Case Western Reserve University School of Medicine, Cleveland, OH, USA. 8. Department of Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. 9. Department of Pediatrics, University of Washington School of Medicine, Seattle, WA, USA. 10. Department of Medicine, National Jewish Health, Denver, CO, USA. 11. Cystic Fibrosis Foundation, Bethesda, MD, USA. 12. Departments of Medicine and Pediatrics, Medical University of South Carolina, Charleston, SC, USA. 13. Cystic Fibrosis Foundation Therapeutics Development Network Coordinating Center, Seattle Children's Research Institute, Seattle, WA, USA; Department of Pediatrics, University of Washington School of Medicine, Seattle, WA, USA; Department of Medicine, University of Washington, Seattle, WA, USA.
Abstract
BACKGROUND: The Standardized Treatment of Pulmonary Exacerbations (STOP) program has the intent of defining best practices in the treatment of pulmonary exacerbations (PEx) in patients with cystic fibrosis (CF). The objective of this analysis was to describe the clinical presentations of patients admitted for intravenous (IV) antibiotics and enrolled in a prospective observational PEx study as well as to understand physician treatment goals at the start of the intervention. METHODS: We enrolled adolescents and adults admitted to the hospital for a PEx treated with IV antibiotics. We recorded patient and PEx characteristics at the time of enrollment. We surveyed treating physicians on treatment goals as well as their willingness to enroll patients in various study designs. Additional demographic and clinical data were obtained from the CF Foundation Patient Registry. RESULTS: Of 220 patients enrolled, 56% were female, 19% were adolescents, and 71% were infected with P. aeruginosa. The mean (SD) FEV1 at enrollment was 51.1 (21.6)% predicted. Most patients (85%) experienced symptoms for ≥7days before admission, 43% had received IV antibiotics within the previous 6months, and 48% received oral and/or inhaled antibiotics prior to IV antibiotic initiation. Forty percent had ≥10% FEV1 decrease from their best value recorded in the previous 6months, but for 20% of patients, their enrollment FEV1 was their best FEV1 recorded within the previous 6months. Physicians reported that their primary treatment objectives were lung function recovery (53%) and improvement of symptoms (47%) of PEx. Most physicians stated they would enroll patients in studies involving 10-day (72%) or 14-day (87%), but not 7-day (29%), treatment regimens. CONCLUSIONS: Based on the results of this study, prospective studies are feasible and physician willingness for interventional studies of PEx exists. Results of this observational study will help design future PEx trials.
BACKGROUND: The Standardized Treatment of Pulmonary Exacerbations (STOP) program has the intent of defining best practices in the treatment of pulmonary exacerbations (PEx) in patients with cystic fibrosis (CF). The objective of this analysis was to describe the clinical presentations of patients admitted for intravenous (IV) antibiotics and enrolled in a prospective observational PEx study as well as to understand physician treatment goals at the start of the intervention. METHODS: We enrolled adolescents and adults admitted to the hospital for a PEx treated with IV antibiotics. We recorded patient and PEx characteristics at the time of enrollment. We surveyed treating physicians on treatment goals as well as their willingness to enroll patients in various study designs. Additional demographic and clinical data were obtained from the CF Foundation Patient Registry. RESULTS: Of 220 patients enrolled, 56% were female, 19% were adolescents, and 71% were infected with P. aeruginosa. The mean (SD) FEV1 at enrollment was 51.1 (21.6)% predicted. Most patients (85%) experienced symptoms for ≥7days before admission, 43% had received IV antibiotics within the previous 6months, and 48% received oral and/or inhaled antibiotics prior to IV antibiotic initiation. Forty percent had ≥10% FEV1 decrease from their best value recorded in the previous 6months, but for 20% of patients, their enrollment FEV1 was their best FEV1 recorded within the previous 6months. Physicians reported that their primary treatment objectives were lung function recovery (53%) and improvement of symptoms (47%) of PEx. Most physicians stated they would enroll patients in studies involving 10-day (72%) or 14-day (87%), but not 7-day (29%), treatment regimens. CONCLUSIONS: Based on the results of this study, prospective studies are feasible and physician willingness for interventional studies of PEx exists. Results of this observational study will help design future PEx trials.
Authors: Michael W Konstan; Wayne J Morgan; Steven M Butler; David J Pasta; Marcia L Craib; Stefanie J Silva; Dennis C Stokes; Mary Ellen B Wohl; Jeffrey S Wagener; Warren E Regelmann; Charles A Johnson Journal: J Pediatr Date: 2007-06-22 Impact factor: 4.406
Authors: Patrick A Flume; Peter J Mogayzel; Karen A Robinson; Randall L Rosenblatt; Lynne Quittell; Bruce C Marshall Journal: Am J Respir Crit Care Med Date: 2010-08-01 Impact factor: 21.405
Authors: Maria T Britto; Uma R Kotagal; Richard W Hornung; Harry D Atherton; Joel Tsevat; Robert W Wilmott Journal: Chest Date: 2002-01 Impact factor: 9.410
Authors: Sanja Stanojevic; Alexandra McDonald; Valerie Waters; Sarah MacDonald; Eric Horton; Elizabeth Tullis; Felix Ratjen Journal: Thorax Date: 2016-08-18 Impact factor: 9.139
Authors: Richard Kraemer; Natascha Deloséa; Pietro Ballinari; Sabina Gallati; Reto Crameri Journal: Am J Respir Crit Care Med Date: 2006-09-07 Impact factor: 21.405
Authors: Sonya L Heltshe; Natalie E West; Donald R VanDevanter; D B Sanders; Valeria V Beckett; Patrick A Flume; Christopher H Goss Journal: Contemp Clin Trials Date: 2017-11-21 Impact factor: 2.226
Authors: Vin Tangpricha; Joshua Lukemire; Yuqing Chen; José Nilo G Binongo; Suzanne E Judd; Ellen S Michalski; Moon J Lee; Seth Walker; Thomas R Ziegler; Rabin Tirouvanziam; Susu M Zughaier; Supavit Chesdachai; Wendy A Hermes; James F Chmiel; Ruth E Grossmann; Amit Gaggar; Patricia M Joseph; Jessica A Alvarez Journal: Am J Clin Nutr Date: 2019-03-01 Impact factor: 7.045
Authors: Ranjani Somayaji; Renee Russell; Jonathan D Cogen; Cristopher H Goss; Sarah E Nick; Milene T Saavedra; Jennifer L Taylor-Cousar; Jerry A Nick; Dave P Nichols Journal: Ann Am Thorac Soc Date: 2019-07
Authors: D R VanDevanter; S L Heltshe; D B Sanders; N E West; M Skalland; P A Flume; C H Goss Journal: J Cyst Fibros Date: 2020-08-13 Impact factor: 5.482
Authors: Kristina Montemayor; Kevin J Psoter; Noah Lechtzin; Sara W Carson; Christian A Merlo; Rebecca H Dezube; Kristin A Riekert; Sarah Allgood; Alexandra Toporek; Mark T Jennings; Natalie E West Journal: J Cyst Fibros Date: 2021-06-03 Impact factor: 5.482